Dexamethasone
"Dexamethasone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-inflammatory 9-fluoro-glucocorticoid.
Descriptor ID |
D003907
|
MeSH Number(s) |
D04.210.500.745.432.769.344 D04.210.500.908.238
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dexamethasone".
Below are MeSH descriptors whose meaning is more specific than "Dexamethasone".
This graph shows the total number of publications written about "Dexamethasone" by people in this website by year, and whether "Dexamethasone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 2 | 3 | 1995 | 4 | 2 | 6 | 1996 | 4 | 2 | 6 | 1997 | 2 | 4 | 6 | 1998 | 1 | 4 | 5 | 1999 | 1 | 4 | 5 | 2000 | 3 | 5 | 8 | 2001 | 4 | 2 | 6 | 2002 | 0 | 1 | 1 | 2003 | 5 | 1 | 6 | 2004 | 1 | 1 | 2 | 2005 | 1 | 2 | 3 | 2006 | 2 | 2 | 4 | 2007 | 1 | 4 | 5 | 2008 | 4 | 4 | 8 | 2009 | 1 | 4 | 5 | 2010 | 5 | 4 | 9 | 2011 | 1 | 8 | 9 | 2012 | 7 | 6 | 13 | 2013 | 2 | 4 | 6 | 2014 | 2 | 8 | 10 | 2015 | 5 | 2 | 7 | 2016 | 1 | 5 | 6 | 2017 | 5 | 4 | 9 | 2018 | 1 | 4 | 5 | 2019 | 11 | 2 | 13 | 2020 | 3 | 8 | 11 | 2021 | 3 | 5 | 8 | 2022 | 1 | 9 | 10 | 2023 | 2 | 8 | 10 | 2024 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Dexamethasone" by people in Profiles.
-
Kant R, Mishra N, Kandhari K, Saba L, Michel C, Reisdorph R, Tewari-Singh N, Pantcheva MB, Petrash JM, Agarwal C, Agarwal R. Dexamethasone targets actin cytoskeleton signaling and inflammatory mediators to reverse sulfur mustard-induced toxicity in rabbit corneas. Toxicol Appl Pharmacol. 2024 02; 483:116834.
-
Mishra N, Kant R, Kandhari K, Tewari-Singh N, Anantharam P, Croutch CR, Pantcheva MB, Petrash JM, Araj H, Agarwal C, Agarwal R. Establishing a Dexamethasone Treatment Regimen To Alleviate Sulfur Mustard-Induced Corneal Injuries in a Rabbit Model. J Pharmacol Exp Ther. 2024 Jan 17; 388(2):469-483.
-
Mishra N, Kant R, Kandhari K, Ammar DA, Tewari-Singh N, Pantcheva MB, Petrash JM, Agarwal C, Agarwal R. Nitrogen Mustard-Induced Ex Vivo Human Cornea Injury Model and Therapeutic Intervention by Dexamethasone. J Pharmacol Exp Ther. 2024 Jan 17; 388(2):484-494.
-
Kumar R, Chanana N, Sharma K, Palmo T, Lee MH, Mishra A, Nolan K, Fonseca Balladares DC, Mickael C, Gupta MD, Thinlas T, Pasha Q, Graham BB. Dexamethasone prophylaxis protects from acute high-altitude illness by modifying the peripheral blood mononuclear cell inflammatory transcriptome. Biosci Rep. 2023 11 30; 43(11).
-
Derman BA, Zonder J, Reece D, Cole C, Berdeja J, Stefka AT, Major A, Kin A, Griffith K, Jasielec J, Jakubowiak AJ. Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Adv. 2023 10 10; 7(19):5703-5712.
-
Lammer NC, Allen MA, Batey RT, Wuttke DS. Quantification of transcriptome changes to investigate the role of glucocorticoid receptor-RNA binding during dexamethasone treatment. BMC Res Notes. 2023 Aug 22; 16(1):181.
-
Lammer NC, Ashraf HM, Ugay DA, Spencer SL, Allen MA, Batey RT, Wuttke DS. RNA binding by the glucocorticoid receptor attenuates dexamethasone-induced gene activation. Sci Rep. 2023 06 09; 13(1):9385.
-
Wilde L, Porazzi P, Trotta R, De Dominici M, Palmisiano N, Keiffer G, Rancani K, Yingling K, Calabretta B, Kasner M. A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia. Leuk Res. 2023 06; 129:107075.
-
Lesokhin A, LeBlanc R, Dimopoulos MA, Capra M, Carlo-Stella C, Karlin L, Castilloux JF, Forsberg P, Parmar G, Tosikyan A, Pour L, Ribrag V, Ribolla R, Abdallah AO, Le Roux N, Dong L, van de Velde H, Mayrargue L, L?pine L, Mac? S, Moreau P. Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study. Cancer Med. 2023 05; 12(9):10254-10266.
-
Derman BA, Chari A, Zonder J, Major A, Stefka AT, Jiang K, Karrison T, Jasielec J, Jakubowiak A. A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Eur J Haematol. 2023 May; 110(5):564-570.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|